Vector Science and Therapeutics Corp. (TSXV: PAIN) has announced that its Board of Directors approved the grant of 150,000 stock options to an officer of the company, subject to TSX Venture Exchange approval. The options carry an exercise price of C$1.80 and are exercisable for five years from the date of grant. The move is a routine but notable compensation disclosure for investors tracking insider alignment and potential share dilution at the Mequon, Wisconsin-based medical device developer.

Key Points

  • Vector Science and Therapeutics Corp. (TSXV: PAIN)
  • Board approved a grant of 150,000 stock options to an officer of the company, pending TSX Venture Exchange approval
  • Options have an exercise price of C$1.80, vest in 25% tranches over three years, and are exercisable for five years from the grant date
  • Investors may be watching for TSX Venture Exchange approval and any further compensation-related disclosures

Option Grant Terms and Vesting Structure for PAIN Officer

The 150,000 options were granted in accordance with the company's existing stock option plan and are subject to a vesting schedule of 25% tranches over a three-year period. The exercise price is set at C$1.80 per share, and the options remain exercisable for five years from the date of grant. The release states that the grant is conditional upon approval from the TSX Venture Exchange. The company did not disclose the identity or specific title of the officer receiving the grant beyond describing them as an officer of the company.

Share Reserve Position Under Vector Science's Option Plan

As of the date of the announcement, the company disclosed that 7,336,610 common shares are reserved for issuance under its stock option plan. Additionally, 8,388,183 options remain available for issuance under the plan. These figures provide investors with a clearer picture of the remaining capacity for future option grants and the overall potential dilutive impact on existing shareholders. The company did not disclose the total number of options currently outstanding or the total issued and outstanding common share count in this announcement.

Vector Science's Biomechanical and Drug Delivery Focus

Vector Science and Therapeutics Corp. develops novel biomechanical devices and active localized drug delivery platforms designed to support site-directed clinical interventions. The company's approach targets situations where precision is critical and systemic risks are considered unacceptable. Headquartered in Mequon, Wisconsin, and listed on the TSX Venture Exchange under the symbol PAIN, the company's work spans both device engineering and localised therapeutic delivery. The immediate share price impact of this option grant was not clear from available public information.